-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) is a highly aggressive non-Hodgkin lymphoma (NHL) subtype with a high incidence in Asia and Latin America
Lymphoma infection immunity
ORIENT-4 is a multi-center, single-arm, phase 2 clinical trial (NCT03228836)
From August 31, 2017 to February 7, 2018, 34 patients were screened , and 28 patients were finally enrolled
Screening for stem cells
As of February 28, 2020, the median follow-up time was 30.
The median follow-up was 30.
Twenty-seven patients (96.
Diabetes Digestion
In summary, the ORIENT-4 study shows that the PD-1 inhibitor sintilimab (sintilimab) is effective and well tolerated in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL)
Original source:
Tao R, Fan L, Song Y, Hu Y, Zhang W, Wang Y, Xu W, Li J.
Leave a message here